Cherian Kripa Elizabeth, Kapoor Nitin, Devasia Anup J, Mathews Vikram, Srivastava Alok, Thomas Nihal, George Biju, Paul Thomas V
Department of Endocrinology, Christian Medical College and Hospital, Vellore, India.
Department of Clinical Haematology, Christian Medical College and Hospital, Vellore, India.
Indian J Hematol Blood Transfus. 2020 Jul;36(3):484-490. doi: 10.1007/s12288-019-01210-w. Epub 2019 Oct 16.
Although haematopoietic stem cell transplant has been successfully employed in the cure of several malignant and non-malignant conditions, survivors often suffer from delayed effects involving the endocrine system and cardio-metabolic risk factors. In this cross-sectional study, we aimed to assess the prevalence of endocrine dysfunction and alterations in metabolic profile in 63 recipients of allogeneic stem cell transplantation as compared to 65 age, sex and body mass index matched controls. Hypogonadism emerged as the most prevalent endocrinopathy, present in 23/60 (38.3%) of subjects, followed by overt and subclinical hypothyroidism in 10/63 (15.9%) of cases. The metabolic parameters, that included plasma glucose and lipid profile were not significantly different between cases and controls. However, insulin resistance, as assessed by surrogate markers employing HOMA IR (3.82 vs. 1.97) and QUICKI (0.338 vs. 0.373) was significantly higher among cases than in controls (< 0.05). Abnormal glucose tolerance was observed in about one-third of the study cohort. The prevalence of overt diabetes (7%) was similar to that in the general population across India (8%); the prevalence of pre-diabetes (21%) was however considerably higher than the national average of 10%. Thus, although the process of haematopoietic stem cell transplant is often curative for the primary haematological disease, it may be associated with various delayed effects on the endocrine system and metabolic profile. Therefore, it is imperative that recipients be screened for the potential development of these late effects subsequent to the transplantation procedure.
尽管造血干细胞移植已成功应用于多种恶性和非恶性疾病的治疗,但幸存者常遭受涉及内分泌系统和心血管代谢危险因素的迟发效应。在这项横断面研究中,我们旨在评估63例异基因干细胞移植受者与65例年龄、性别和体重指数相匹配的对照者相比,内分泌功能障碍的患病率以及代谢谱的改变。性腺功能减退是最常见的内分泌病,在23/60(38.3%)的受试者中出现,其次是显性和亚临床甲状腺功能减退,在10/63(15.9%)的病例中出现。包括血糖和血脂谱在内的代谢参数在病例组和对照组之间没有显著差异。然而,采用HOMA-IR(3.82对1.97)和QUICKI(0.338对0.373)等替代指标评估的胰岛素抵抗在病例组中显著高于对照组(<0.05)。约三分之一的研究队列观察到糖耐异常。显性糖尿病的患病率(7%)与印度全国普通人群的患病率(8%)相似;然而,糖尿病前期的患病率(21%)远高于全国平均水平10%。因此,尽管造血干细胞移植过程通常可治愈原发性血液疾病,但它可能与对内分泌系统和代谢谱的各种迟发效应有关。因此,在移植手术后对受者进行这些迟发效应潜在发展的筛查至关重要。